Latest National Institute of Neurological Disorders and Stroke Stories
BOULDER, Colo., Oct. 15 /PRNewswire/ -- Bolder BioTechnology, Inc.
Lixte Biotechnology Holdings has announced that the National Institute of Neurological Disorders and Stroke, National Institutes of Health and Lixte have filed a joint patent application for a new cancer biomarker.
EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc.
A new study about National Institutes of Health research grants ranks Utah eighth among states for new business activity for every $1 million in NIH funding. The report from Families USA shows that Utah generated $2.3 million, above the national average of $2.21 million.
The National Institute of Neurological Disorders and Stroke, National Institutes of Health, and Lixte Biotechnology Holdings have extended co-operative research and development agreement to develop drugs for the treatment of brain cancers.
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc.
Most people with a rare type of dementia called primary progressive aphasia (PPA) have a specific combination of prion gene variants, a new study shows.
Daily aches and discomfort may become more common with age, but elderly Americans shouldn't have to increase their dosage of narcotic pain relievers to keep up with the pain, researchers report.
Insomniacs can now try another sleeping pill for desperately needed slumber. Lunesta, from Sepracor Inc., is the latest entry into the sleep medication market, and it has the distinction of being the only such medication approved for long-term use by the U.S. Food and Drug Administration (FDA).
- a slit in a tire to drain away surface water and improve traction.